Watchlist Price Alert

Septerna Inc. (SEPN)

NASDAQ: SEPN · Real-Time Price · USD

10.52

0.05 (0.48%)

At close: Jun 23, 2025, 3:59 PM

10.66

1.38%

After-hours: Jun 23, 2025, 07:59 PM EDT

0.48% (1D)

Bid	10.43
Market Cap	468.53M
Revenue (ttm)	725K
Net Income (ttm)	-27.77M
EPS (ttm)	-1.78
PE Ratio (ttm)	-5.91
Forward PE	-4.87
Analyst	Buy

Ask	10.66
Volume	417,932
Avg. Volume (20D)	1,057,682
Open	10.44
Previous Close	10.47
Day's Range	10.26 - 11.35
52-Week Range	4.17 - 28.99
Beta	4.26

About SEPN

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol SEPN

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for SEPN stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Why Price Moved

1 month ago

-2.77%

SEPN stock has given up its prior gain. Septerna s... Unlock content with Pro Subscription

1 month ago

-2.77%

Septerna shares are trading higher after the company reported better-than-expected Q1 sales results.

News

23 hours ago · benzinga.com

Analyst Flags Septerna As Undervalued Biotech Play With Significant Upside

On Monday, HC Wainwright initiated coverage on Septerna, Inc. SEPN, citing a next-generation drug design platform aimed at hitherto-undruggable targets.

1 month ago · marketbeat.com

Analysts Think These Stocks Could More Than Double in Value

Persistent volatility has plagued the S&P 500 for much of 2025, prompting widespread caution among many investors amid the uncertainties of trade battles, tariffs, domestic policy, and more. Investors...

1 month ago · zacks.com

Does Septerna, Inc. (SEPN) Have the Potential to Rally 151.27% as Wall Street Analysts Expect?

The mean of analysts' price targets for Septerna, Inc. (SEPN) points to a 151.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among ...

1 month ago · seekingalpha.com

Septerna: Novo's Investment In Incretin Program Intrigues - One For The Watchlist

Septerna's partnership with Novo Nordisk is a strong endorsement, but the $195m upfront is modest (by Big Pharma standards) and milestone payments are not guaranteed. The company's innovative GPCR pla...

1 month ago · seekingalpha.com

Septerna: Deal With Novo Nordisk Is A Game Changer While It Still Trades Well Below Net Cash

Septerna's partnership with Novo Nordisk validates its GPCR drug discovery platform and injects $195 million in upfront cash, with potential for more than $2 billion in milestone payments. The stock t...

1 month ago · zacks.com

ETFs to Capitalize on the Novo Nordisk-Septerna Deal

Novo Nordisk announces a $2.2 billion deal with Septerna to tap the growing obesity treatment market.

1 month ago · zacks.com

Septerna Stock Surges on Oral Obesity Drug Deal With Novo Nordisk

SEPN is entitled to receive around $2.2 billion from NVO under the new collaboration deal, which aims to develop oral pills for obesity and other diseases.

1 month ago · proactiveinvestors.com

Septerna stock pops on partnership with Novo Nordisk to develop obesity therapies

Septerna (NASDAQ:SEPN) shares surged almost 50% after the announcement of an exclusive global collaboration and license deal with Novo Nordisk (NYSE:NVO) to develop oral small molecule medicines targe...